Source link : https://www.newshealth.biz/health-news/fda-approves-new-il-31-drug-for-eczema/
The FDA approved nemolizumab (Nemluvio) in combination with prescription topical agents for the treatment of moderate-to-severe atopic dermatitis, drugmaker Galderma announced. A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals 12 years and older with eczema that is not sufficiently controlled with topical corticosteroids and/or calcineurin inhibitors. Nemolizumab is […]
Author : News Health
Publish date : 2024-12-16 16:54:20
Copyright for syndicated content belongs to the linked Source.